

Non-Small Cell Lung Cancer (NSCLC)

**A Study of MTIG7192A in Combination With Atezolizumab in  
Chemotherapy-Naïve Patients With Locally Advanced or Metastatic  
Non-Small Cell Lung Cancer**

**Trial Status**  
Active, not recruiting

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT03563716 2018-000280-81  
GO40290

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This study will evaluate the safety and efficacy of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in chemotherapy-naïve patients with locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), excluding patients with a sensitizing EGFR mutation or ALK translocation.

**Genentech, Inc.**  
Sponsor

**Phase 2**  
Phase

**NCT03563716 2018-000280-81 GO40290**  
Trial Identifiers

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥ 18 Years

**Healthy Volunteers**  
No